Category

News
FTC Clinical Study Standards BMC

FTC Sets the Clinical Study Standards for Advertising Health-related Claims – Part Two

In the previous post, I had focused on the implications of the FTC Order issued last October as it pertains to the type of clinical studies required if a clinic or health care provider wanted to make health-related claims about the therapies they provide and to advertise these claims. The FTC obtained Federal court endorsement...
Read More
FTC and umbilical cord-derived stem cells

FTC Sets the Clinical Study Standards for Advertising Health-related Claims – Part One

The recent FTC actions against a physician who practiced miraculous regenerative medicine suggest a tightening of the allowed actions and activities of the field with respect to making claims and advertising, which clinics use to differentiate themselves from the group down the street. However, the recent FTC court action shows the perils going forward of...
Read More
False claims about amniotic stem cells

FTC Actions Against Stem Cell Clinics Making False Claims about Amniotic Fluid Products – Part Five

Over the previous four posts, I have reviewed the FTC’s legal actions taken against a physician who advertised what I call miraculous regenerative medicine on the Internet, in which amazing claims of therapeutic benefit were announced for treating virtually any pathologic condition, including ALS, MS, COPD, chronic kidney disease, autism, etc. I provided examples from the...
Read More
FTC Actions Against False Claims

FTC Actions Against Stem Cell Clinics Making False Claims about Amniotic Fluid Products – Part Four

In the previous three posts (Part One, Part Two, Part Three), I have been reviewing aspects of the FTC’s recent court case against Dr. Henderson, who was charged by the FTC with false advertising by making clinically-unsupported claims about the therapeutic power of amniotic stem cells. Dr. Henderson acknowledged engaging in false advertising and making...
Read More
FTC Against Dr. Henderson

FTC Actions Against Stem Cell Clinics Making Deceptive Claims about Amniotic Fluid Products – Part Three

For the past two posts (Part One and Part Two), I have covered the case of Dr. Bryn Henderson, who was taken to court in October by the Federal Trade Commission (FTC) over his completely unsupported and deceptive claims concerning the miraculous therapeutic benefit of amniotic stem cells to treat every aliment known to mankind...
Read More
FTC Against False Claims

FTC Actions Against Stem Cell Clinics Making Deceptive Claims about Amniotic Fluid Products – Part Two

In the last post, I had introduced the sins of Dr. Henderson, who was cited by the FTC for advertising MRM—miraculous regenerative medicine. Needless to say, the FTC took exception to the outlandish and false claims Dr. Henderson made on his now-inaccessible website(s), so I will perform a public service by sharing with you my...
Read More
FTC Against Deceptive Claims

FTC Actions Against Stem Cell Clinics Making Deceptive Claims about Amniotic Fluid Products – Part One

By now, I am sure most folks in the regenerative medical community have heard about the Federal Trade Commission (FTC) going to court and formalizing an Order that effectively shut down a physician who really was pushing the limits and engaging in blatantly false advertisement to lure patients to his clinics to pay a lot...
Read More
BMC to Treat Orthopedic Conditions

Differences Between IV Infusion of BMC and Amniotic Fluid – Part Two

In the previous post, I had begun a review of the distinctions between the potential utility of an IV infusion of a patient’s bone marrow concentrate and the utter futility of using amniotic fluid products currently on the market to treat anything, whether by IV or site-specific injection. One of the issues I commented on...
Read More
BMC Therapy vs Amniotic Fluid

Differences Between IV Infusion of BMC and Amniotic Fluid – Part One

No doubt some of you who regularly read my posts probably thought that I had lost my mind during the just completed set of three posts on considerations for using IV infusion with autologous BMC to boost up cellularity in a patient’s depleted bone marrow depots. I suspect you couldn’t believe that I would write posts...
Read More
BMC via IV Therapy

Considerations On the Regulatory Status of IV Administration of BMC: A Useful Shot in the Arm? Part Three

Over the previous couple of posts, I have been reviewing the love/hate relationship the FDA seems to have with therapy provided by an IV route. They issued a blanket determination in the MM/HU Guidance that IV therapies of HCT/Ps would be considered risky and therefore physicians offering IV therapies of HCT/Ps would be more rapidly...
Read More
1 2 3 4 10